SE0104203L - Farmaceutiska formuleringar och metoder innefattande intranasalt morfin - Google Patents

Farmaceutiska formuleringar och metoder innefattande intranasalt morfin

Info

Publication number
SE0104203L
SE0104203L SE0104203A SE0104203A SE0104203L SE 0104203 L SE0104203 L SE 0104203L SE 0104203 A SE0104203 A SE 0104203A SE 0104203 A SE0104203 A SE 0104203A SE 0104203 L SE0104203 L SE 0104203L
Authority
SE
Sweden
Prior art keywords
morphine
pharmaceutical formulations
methods involving
pharmaceutically acceptable
intranasal morphine
Prior art date
Application number
SE0104203A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Other versions
SE0104203D0 (sv
Inventor
Raja G Achari
Charanjit R Behl
Jorge C Demeireles
Ramneik Dua
Anthoney P Sileno
Vincent D Romeo
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of SE0104203D0 publication Critical patent/SE0104203D0/xx
Publication of SE0104203L publication Critical patent/SE0104203L/

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SE0104203A 1999-06-16 2001-12-14 Farmaceutiska formuleringar och metoder innefattande intranasalt morfin SE0104203L (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33453799A 1999-06-16 1999-06-16
PCT/US2000/014157 WO2000076506A1 (fr) 1999-06-16 2000-05-23 Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale

Publications (2)

Publication Number Publication Date
SE0104203D0 SE0104203D0 (sv) 2001-12-14
SE0104203L true SE0104203L (sv) 2001-12-14

Family

ID=23307687

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0104203A SE0104203L (sv) 1999-06-16 2001-12-14 Farmaceutiska formuleringar och metoder innefattande intranasalt morfin

Country Status (30)

Country Link
US (1) US6677346B1 (fr)
EP (2) EP1183027A4 (fr)
JP (1) JP2003501467A (fr)
KR (1) KR20020016831A (fr)
AU (1) AU774175B2 (fr)
BG (1) BG106221A (fr)
BR (1) BR0012082A (fr)
CA (1) CA2374877C (fr)
CZ (1) CZ20014399A3 (fr)
DE (1) DE10084709T1 (fr)
DK (1) DK200101859A (fr)
EE (1) EE200100677A (fr)
ES (1) ES2197792B1 (fr)
FI (1) FI20012462A7 (fr)
GB (1) GB2367005A (fr)
HR (1) HRP20010926A2 (fr)
HU (1) HUP0201856A3 (fr)
IS (1) IS6202A (fr)
LT (1) LT4976B (fr)
LU (1) LU90859B1 (fr)
LV (1) LV12859B (fr)
MX (1) MXPA01012879A (fr)
NO (1) NO20015931L (fr)
NZ (1) NZ515783A (fr)
PL (1) PL352556A1 (fr)
SE (1) SE0104203L (fr)
SI (1) SI20850A (fr)
SK (1) SK18172001A3 (fr)
TR (1) TR200103613T2 (fr)
WO (1) WO2000076506A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
EP1418862A4 (fr) * 2001-06-29 2010-06-09 Leon J Lewandowski Therapie de sevrage individualisee en cas de dependance
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PL2486942T3 (pl) 2004-11-24 2019-05-31 Meda Pharmaceuticals Inc Kompozycje zawierające azelastynę oraz sposoby ich stosowania
US9415034B2 (en) * 2005-01-05 2016-08-16 National Defense Medical Center Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B)
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
GB2477545B (en) * 2010-02-05 2011-12-21 Special Products Ltd A liquid morphine composition for buccal administration
HRP20180233T1 (hr) 2011-05-13 2018-06-01 Euro-Celtique S.A. Intranazalni farmaceutski oblici doziranja koji sadrže nalokson
US20150231130A1 (en) 2012-07-26 2015-08-20 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
WO2015095389A1 (fr) * 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions pour administration de médicaments
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
EP3528797A1 (fr) * 2016-10-21 2019-08-28 Somniferum Labs LLC Compositions, méthodes et kits pour l'administration par inhalation sûre d'opioïdes ciblés pour le traitement de la douleur et de la dépendance
MA50394A (fr) * 2017-10-20 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant un agoniste de récepteur d'opioïde en tant que substances actives, leurs procédés de fabrication et leurs utilisations thérapeutiques
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4464376A (en) 1982-07-22 1984-08-07 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE69434304T2 (de) * 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
CA2266898A1 (fr) * 1996-09-27 1998-04-02 Nastech Pharmaceutical Co., Inc. Formulations intranasales pour favoriser le sommeil et leur procede d'utilisation

Also Published As

Publication number Publication date
NO20015931L (no) 2002-02-08
EE200100677A (et) 2003-02-17
US6677346B1 (en) 2004-01-13
CA2374877A1 (fr) 2000-12-21
MXPA01012879A (es) 2003-06-24
PL352556A1 (en) 2003-08-25
HUP0201856A3 (en) 2004-12-28
GB2367005A (en) 2002-03-27
LT4976B (lt) 2002-12-30
GB0128383D0 (en) 2002-01-16
AU5156100A (en) 2001-01-02
SE0104203D0 (sv) 2001-12-14
CZ20014399A3 (cs) 2002-06-12
EP1183027A1 (fr) 2002-03-06
DK200101859A (da) 2001-12-12
HUP0201856A1 (en) 2002-09-28
EP1419774A1 (fr) 2004-05-19
DE10084709T1 (de) 2002-09-26
SK18172001A3 (sk) 2002-07-02
WO2000076506A1 (fr) 2000-12-21
SI20850A (sl) 2002-10-31
LU90859B1 (en) 2002-01-24
LV12859B (en) 2002-12-20
IS6202A (is) 2001-12-14
NZ515783A (en) 2004-05-28
NO20015931D0 (no) 2001-12-04
ES2197792A1 (es) 2004-01-01
KR20020016831A (ko) 2002-03-06
LT2001119A (en) 2002-07-25
AU774175B2 (en) 2004-06-17
FI20012462L (fi) 2002-01-16
BG106221A (bg) 2002-08-30
ES2197792B1 (es) 2005-05-01
JP2003501467A (ja) 2003-01-14
BR0012082A (pt) 2002-05-07
TR200103613T2 (tr) 2004-08-23
HRP20010926A2 (en) 2003-04-30
CA2374877C (fr) 2004-04-13
EP1183027A4 (fr) 2003-02-05
FI20012462A7 (fi) 2002-01-16

Similar Documents

Publication Publication Date Title
SE0104203D0 (sv) Farmaceutiska formuleringar och metoder innefattande intranasalt morfin
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
WO2000021515A3 (fr) Codeine intra-nasale permettant d'eliminer rapidement la toux et de soulager rapidement la douleur
EP1355564A4 (fr) Methode et dispositif d'administration de medicament et/ou de placebo
ATE361077T1 (de) Indanylderivate zur behandlung von atemwegserkrankungen
GB9902689D0 (en) Organic compounds
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
DK1156790T3 (da) Kombinationer af formoterol og motetason furat
GR3019012T3 (en) Therapeutic compositions for intranasal administration which include ketorolac TM.
PL312683A1 (en) Pharmaceutical solutions free of organic salts for nasal administration
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
ITTO20020102A1 (it) Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
DK1105132T3 (da) Anvendelse af R(+)-G(A)-(2,3-dimethoxyphenyl)-1-[2-(4-fluorphenyl)ethyl]-4-piperidinemethanol til behandling af obstruktiv søvnapnø
EE200300555A (et) Morfiini sisaldav farmatseutiline preparaat ninasiseseks manustamiseks ning meetod valuvaigistava või tuimastava reaktsiooni esilekutsumiseks imetajal

Legal Events

Date Code Title Description
NAV Patent application has lapsed